Strong Research Focus PMV Pharmaceuticals specializes in precision oncology by targeting mutant p53, positioning it as a leader in personalized cancer therapies. This focus presents opportunities to partner with companies developing complementary diagnostic tools or targeted treatments for mutant p53-related cancers.
Strategic Collaborations Recent partnerships with top-tier cancer research centers such as MD Anderson and MSK underscore the company's active engagement in clinical trial development. Sales opportunities exist in providing advanced laboratory services, clinical data management, or research support for ongoing and future trials.
Robust Funding and Growth With $136M in funding and recent product development initiatives, PMV is in a growth phase, seeking innovative solutions for drug discovery, formulation, and manufacturing. Suppliers of bioprocessing equipment, formulation technologies, or API development services could benefit from targeting PMV’s expansion needs.
Focus on Clinical Advancement The prioritization of PC14586 and ongoing clinical trials indicates a pipeline readiness that may require clinical support services, regulatory consulting, or commercialization planning, offering multiple touchpoints for engagement with service providers.
Emphasis on Technology Integration PMV employs advanced tech stacks like React, Drupal, and NetSuite, suggesting a commitment to innovative digital infrastructure. Vendors specializing in biotech IT solutions, data analytics, or cybersecurity may find strategic collaboration opportunities to support the company’s digital ecosystem and data integrity.
PMV Pharmaceuticals, Inc. uses 8 technology products and services including Drupal, Module Federation, NetSuite, and more. Explore PMV Pharmaceuticals, Inc.'s tech stack below.
| PMV Pharmaceuticals, Inc. Email Formats | Percentage |
| FLast@pmvpharma.com | 100% |
Biotechnology ResearchNew Jersey, United States51-200 Employees
At PMV, we believe that by specifically targeting each mutant p53 we can fundamentally disrupt the course of cancer. Our research and development efforts are dedicated to selectively targeting mutant p53, providing unique therapies for any patient whose tumor harbors these gene mutations.
Company Overview
Funding & FinancialsPMV Pharmaceuticals, Inc. has raised a total of $136M of funding over 2 rounds. Their latest funding round was raised on Nov 13, 2019 in the amount of $62Mas a Series C.
PMV Pharmaceuticals, Inc.'s revenue is estimated to be in the range of $10M$25M
Funding & FinancialsPMV Pharmaceuticals, Inc. has raised a total of $136M of funding over 2 rounds. Their latest funding round was raised on Nov 13, 2019 in the amount of $62Mas a Series C.
PMV Pharmaceuticals, Inc.'s revenue is estimated to be in the range of $10M$25M
1-888-653-2347 
support@leadiq.com